In this low-grade GEMM glioma model, the median survival in the IgG control group (n = 20) was 110.5 days, the anti–PD-1–treated group (n = 20) median survival was 134.5 days (log-rank test, P = 0.64 vs. IgG), and the anti-TIM3–treated group (n = 21) was 253 days (log-rank test, P = 0.01 vs. IgG; Figure 5H). This evidence concerns the gene HAVCR2 and glioma.